The Board of Regents of the University of Oklahoma Patent applications |
Patent application number | Title | Published |
20160060315 | PEPTIDE COMPOUNDS AND METHODS OF PRODUCTION AND USE THEREOF - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptide compounds. | 03-03-2016 |
20160000893 | TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS - A set of target peptides are presented by HLA A*0201 on the surface of ovarian cancer cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., ovarian cancer, (b) function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex. | 01-07-2016 |
20150374995 | CARDIAC NEUROMODULATION AND METHODS OF USING SAME - The present invention relates in general to methodologies for the treatment quenching preconditioning and communication between the intrinsic cardiac nervous system and an electrical stimulus. In particular, the present invention utilizes spinal cord stimulation to alter and/or affect the intrinsic cardiac nervous system and thereby protect the myocytes, stabilize myocardial electrical instability and/or alleviate or diminish cardiac pathologies. | 12-31-2015 |
20150374785 | Peptide Compounds and Methods of Production and Use Thereof - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides. | 12-31-2015 |
20150105686 | IMPLANTABLE ELECTRODE ASSEMBLY - An electrode assembly includes a retainer, a flexible sheath, and an electrode. The retainer may include a plurality of clasping arms. The retainer is movable to an open position and a closed position. The flexible Sheath is positioned below a lower surface of the retainer. The flexible sheath is at least partially surrounded by the clasping arms of the retainer. The retainer is able to hold the flexible sheath around a target tissue when the retainer is in the closed position. The electrode is configured for conducting electrical signals to or from the target tissue. The electrode is connected to at least one of the retainer and the flexible sheath. The retainer is able to hold the electrode in electrical communication with the target tissue when the retainer is disposed around the target tissue in the closed position. | 04-16-2015 |
20140292563 | Radar System and Methods for Making and Using Same - A transmitter front end circuit is described. The transmitter front end circuit is provided with a radar transmitter port, a radar receiver port, a radar amplifier, a coupler, a radar antenna input and a signal director. The radar amplifier has a low power side receiving a transmit signal having a transmit waveform modulated onto a carrier frequency from the radar transmitter port, and a high power side outputting an amplified transmit waveform suitable for transmission to a radar antenna. The coupler is coupled to the high power side of the radar amplifier to sample the amplified transmit waveform. The radar antenna input is configured to receive return signals from a radar antenna. And, the signal director selectively directs the sample of the amplified transmit waveform and the return signals to the radar receiver port. | 10-02-2014 |
20140256613 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Peptide compositions are disclosed that include fragments of surfactant protein-A, or a derivative thereof, wherein the fragment binds to TLR4. Methods of producing and using the peptide compositions are also disclosed. | 09-11-2014 |
20140162938 | PEPTIDE COMPOUNDS AND METHODS OF PRODUCTION AND USE THEREOF - Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides. | 06-12-2014 |
20140155497 | HEPAROSAN-BASED BIOMATERIALS AND COATINGS AND METHODS OF PRODUCTION AND USE THEREOF - Biomaterial compositions that include an isolated heparosan polymer are disclosed, as well as kits containing such biomaterial compositions and methods of producing and using such biomaterial compositions. | 06-05-2014 |
20140155333 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT USING TARGETED CARBON NANOTUBES - Compositions for detecting and/or destroying cancer tumors and/or cancer cells via photodynamic therapy are disclosed, as well as methods of use thereof. The compositions comprise a linking protein or peptide attached to or otherwise physically associated with a carbon nanotube to form a targeted protein-carbon nanotube complex. | 06-05-2014 |
20140154874 | METHOD OF MAKING SEMICONDUCTOR MATERIALS AND DEVICES ON SILICON SUBSTRATE - A crystalline structure comprising a substrate, which has a surface. The surface has one or more wells formed therein defining one or more growing area and at least one layer of dissimilar crystalline material epitaxially grown on the growing area. A method of making a crystalline structure having a low threading dislocation density comprising the steps of (a) patterning a surface of a substrate material such that one or more wells defining a growing area is formed therein; and (b) epitaxially growing at least one strained layer of dissimilar crystalline material on the growing area of the surface of the substrate material, such that the threading dislocation density of the at least one strained layer is reduced by the one or more wells. | 06-05-2014 |
20140154753 | TESTOSTERONAN, A NOVEL HEPAROSAN ANALOG, TESTOSTERONAN SYNTHASE, AND METHODS OF PRODUCTION AND USE THEREOF - Testosteronan, a heparosan analog having the structure [-4-D-GlcUA-α1,4-D-GlcNAc-α1-] | 06-05-2014 |
20140119162 | Ultrasonic Communication System for Communication Through RF-Impervious Enclosures and Abutted Structures - An ultrasonic communication system comprising an enclosure, a first module and a second module is described. The enclosure has an internal surface, an external surface, and defines at least one metal channel. The first module comprises an ultrasonic transceiver disposed within the enclosure. The first module is positioned on the internal surface of the enclosure and is capable of transmitting and/or receiving modulated ultrasonic waves via the metal channel. The second module is positioned on the external surface of the enclosure and is adapted to transmit and/or receive modulated ultrasonic waves from the first module via the metal channel. | 05-01-2014 |
20140117238 | METHOD AND APPARATUS FOR DETECTING AN ANALYTE - Disclosed herein are methods and mid-IR detection apparatus to measure analytes in gas or liquid phase. Solid state cooling of a crystalline lattice is effectively achieved with the controlled flow of charge carriers that absorb thermal energy from the semiconductor material which senses mid-IR photons. Reduction in temperature improves signal-to-noise ratios thus improving molecular sensitivity. In one embodiment the apparatus is used to detect a biomarker. | 05-01-2014 |
20140107066 | HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF - High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers. | 04-17-2014 |
20140100411 | TREATMENT OF CARDIOVASCULAR DISORDERS WITH TARGETED NANOPARTICLES - Methods for treating various cardiovascular disorders include targeted delivery of calcium ions for permanently impairing a portion of the autonomic nervous system (ANS). Targeted delivery may be via magnetically-targetable nanoparticles. | 04-10-2014 |
20140056972 | ANTI-DCLK1 MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF - Monoclonal antibodies against DCLK1 and conjugates containing these monoclonal antibodies are disclosed. Methods of producing and using these monoclonal antibodies are also disclosed. | 02-27-2014 |
20140045759 | PEPTIDE COMPOSITIONS THAT DOWNREGULATE TLR-4 SIGNALING PATHWAY AND METHODS OF PRODUCING AND USING SAME - Compositions that include isolated peptides that inhibit TLR-4 signaling pathways and inflammation are disclosed. Methods of producing and using the compositions to inhibit TLR-4 signaling and/or inflammation are also disclosed herein. | 02-13-2014 |
20140044771 | ENZYME PRODRUG CANCER THERAPY SELECTIVELY TARGETED TO TUMOR VASCULATURE AND METHODS OF PRODUCTION AND USE THEREOF - Methods of treating cancer by targeting tumor vasculature using an enzyme prodrug cancer therapy treatment are provided. | 02-13-2014 |
20140024685 | GAMMA-GLUTAMYL TRANSPEPTIDASE INHIBITORS AND METHODS OF USE - Compositions that are effective in inhibiting gamma-glutamyl transpeptidase are disclosed. Methods of producing and using these compositions are also disclosed. | 01-23-2014 |
20130315604 | MOBILE BI-DIRECTIONAL FREE-SPACE OPTICAL NETWORK - The system provides a mobile, full bi-directional, free-space optical (FSO) network providing networkability and internet connectivity. Each mobile system has a FSO transceiver communicating via line-of-sight (LOS) with a stationary FSO transceiver. Alternatively, the mobile system communicates with a relay FSO transceiver that is in contact with another relay and/or a stationary FSO transceiver. The system has diversity of wavelengths through a multi- wavelength system operating predominately in the infrared spectrum. The network is directionally constrained by the optical components to reduce interference with other networks. Pointing, acquisition, and tracking (PAT) of the network optical signal generator and receivers assists optical performance. | 11-28-2013 |
20130261079 | HIGH MOLECULAR WEIGHT HEPAROSAN POLYMERS AND METHODS OF PRODUCTION AND USE THEREOF - High molecular weight heparosan polymers are described, as are methods of producing and using the high molecular weight heparosan polymers. | 10-03-2013 |
20130247951 | THERMOELECTRIC MATERIAL WITH HIGH CROSS-PLANE ELECTRICAL CONDUCTIVITY IN THE PRESENCE OF A POTENTIAL BARRIER - Embodiments of a thermoelectric material having high cross-plane electrical conductivity in the presence of one or more Seebeck coefficient enhancing potential barriers and methods of fabrication thereof are disclosed. In one embodiment, a thermoelectric material includes a first matrix material layer, a barrier layer, and a second matrix material layer. The barrier layer is a short-period superlattice structure that includes multiple superlattice layers. Each superlattice layer has a high energy sub-band and a low energy sub-band. For each superlattice layer, the energy level of the high energy sub-band of the superlattice layer is resonant with the energy level of the low energy level sub-band of an adjacent superlattice layer and/or the energy level of the low energy sub-band of the superlattice layer is resonant with the energy level of the high energy sub-band of an adjacent superlattice layer. As a result, cross-plane electrical conductivity of the thermoelectric material is improved. | 09-26-2013 |
20130245385 | SELECTIVE ANTI-HLA ANTIBODY REMOVAL DEVICE AND METHODS OF PRODUCTION AND USE THEREOF - An anti-MHC removal device includes a serologically active, soluble MHC moiety covalently coupled to a solid support. Methods of production include covalently coupling the serologically active, soluble MHC moiety to the solid support. Methods of use of the anti-MHC removal device include contacting a biological sample with the device so that antibodies specific for the MHC moiety are removed from the biological sample. | 09-19-2013 |
20130237689 | SOLUBLE HLA CLASS II COMPLEXES AND METHODS OF PRODUCTION AND USE THEREOF - The production of soluble HLA class II molecules, as well as methods of using the soluble HLA class II molecules so produced, are described herein. | 09-12-2013 |
20130225694 | COMPOSITIONS AND METHODS OF INHIBITING RETINAL DEGENERATION - Nitrone-based compositions are disclosed that may be utilized for the prevention and treatment of a variety of ophthalmic diseases or conditions where RPE65 protein isomerohydrolase is implicated. Methods of production and use of said nitrone-based compositions, as well as pharmaceutical and ophthalmic compositions containing same, are disclosed. | 08-29-2013 |
20130212125 | BIOINFORMATICS SEARCH TOOL SYSTEM FOR RETRIEVING AND SUMMARIZING GENOTYPIC AND PHENOTYPIC DATA FOR DIAGNOSING PATIENTS - A computer system having a processor, non-transitory memory and a communication system is described. The communication system is coupled to a network and communicates with one or more genetic databases using an internet protocol. The non-transitory memory stores processor executable code to cause the processor to (1) receive data indicative of genetic array data of a patient via the communication system, (2) conduct, via the communication system and the network, at least one query of one or more genetic databases of genotypic data and phenotypic data using the data indicative of patient genetic data and phenotypic data, and (3) provide results of the at least one query to provide a clinical synopsis of the patient. | 08-15-2013 |
20130195761 | COMPOSITIONS COMPRISING ANTI-CAP37 ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF - Compositions comprising antibodies raised against CAP37 and isoforms thereof, along with antigen binding fragments thereof, are disclosed. These compositions have many uses, such as in detection of CAP37 and as an early detection marker for various disease conditions. In addition, the compositions may be used therapeutically to inhibit, mitigate, or modulate certain cellular activities involving CAP37 or to monitor a disease progression or the success of a disease treatment. | 08-01-2013 |
20130184323 | TREATMENT OF ENDOPLASMIC RETICULUM STRESS-RELATED DISEASES AND CONDITIONS - A method of treating a disease or condition associated with at least one of a cellular accumulation of unfolded and/or misfolded proteins, an abnormal unfolded protein response (UPR), an endoplasmic reticulum (ER) stress, and an abnormal autophagy response, is disclosed. The method may include administering one or more flexible heteroarotinoid compounds which target, bind to, disrupt, and/ or modulate the activity of one or more of heat shock proteins | 07-18-2013 |
20130164368 | HEPAROSAN POLYMERS AND METHODS OF MAKING AND USING SAME FOR THE ENHANCEMENT OF THERAPEUTICS - Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. | 06-27-2013 |
20130143235 | COMPARATIVE LIGAND MAPPING FROM MHC CLASS I POSITIVE CELLS - Compositions that include isolated, functionally active, recombinantly produced class I HLA trimolecular complexes that include epitopes unique to breast cancer cells are disclosed. | 06-06-2013 |
20130096093 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 04-18-2013 |
20130009132 | LOW THERMAL CONDUCTIVITY MATERIAL - Embodiments of a material having low cross-plane thermal conductivity are provided. Preferably, the material is a thermoelectric material. In general, the thermoelectric material is designed to block phonons, which reduces or eliminates heat transport due to lattice vibrations and thus cross-plane thermal conductivity. By reducing the thermal conductivity of the thermoelectric material, a figure-of-merit (ZT) of the thermoelectric material is improved. In one embodiment, the thermoelectric material includes multiple superlattice periods that block, or reflect, multiple phonon wavelengths. | 01-10-2013 |
20120214772 | COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 08-23-2012 |
20120157534 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention in a preferred embodiment is a combination of 5-aminosalicylic acid or 4-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 06-21-2012 |
20120149666 | COMPOSITIONS AND METHODS OF TREATMENT FOR INFLAMMATORY DISEASES - Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases. | 06-14-2012 |
20120055528 | THERMOELECTRIC MATERIALS - A thermoelectric material having a high ZT value is provided. In general, the thermoelectric material is a thin film thermoelectric material that includes a heterostructure formed of IV-VI semiconductor materials, where the heterostructure includes at least one potential barrier layer. In one embodiment, the heterostructure is formed of IV-VI semiconductor materials and includes a first matrix material layer, a potential barrier material layer adjacent to the first matrix material layer and formed of a wide bandgap material, and a second matrix material layer that is adjacent the potential barrier material layer opposite the first matrix material layer. A thickness of the potential barrier layer is approximately equal to a mean free path distance for charge carriers at a desired temperature. | 03-08-2012 |
20110071117 | COMBINATIONS OF ANTIOXIDANTS AND ANTI-INFLAMMATORY DRUGS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein are compositions comprising 5-aminosalicylic acid (5-ASA), or a pharmaceutically acceptable salt thereof and an antioxidant, or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods of treating an inflammatory bowel disease in a subject, reducing cytokine gene expression in colonic tissue of a subject, and reducing myeloperoxide activity in colonic tissue of a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising 5-ASA, or a pharmaceutically acceptable salt thereof, and an antioxidant, or a pharmaceutically acceptable salt thereof. | 03-24-2011 |
20100203606 | ISOLATION AND CHARACTERIZATION OF NOVEL CLOSTRIDIAL SPECIES - A novel clostridia bacterial species ( | 08-12-2010 |